Colossal Raises $200M in Series C Funding Led by TWG Global
Colossal, a pioneering biotechnology company focused on de-extinction and genetic restoration, has successfully raised $200 million in its Series C funding round. The round was led by TWG Global, a prominent venture capital firm known for supporting cutting-edge companies at the forefront of scientific innovation. This latest funding will enable Colossal to further its mission of advancing genetic technologies and restoring extinct species, while also expanding its global reach and capabilities.
Founded in 2021, Colossal has quickly become a leader in the field of genetic engineering and de-extinction. The company leverages groundbreaking technologies like gene editing and CRISPR to resurrect extinct species, such as the woolly mammoth and the Tasmanian tiger, with the ultimate goal of reversing biodiversity loss and combating climate change. Colossal’s innovative approach seeks to use genetic restoration to reintroduce these species into their native ecosystems, which could have a profound impact on both ecological restoration and carbon sequestration.
TWG Global’s investment underscores the growing confidence in Colossal’s mission and the potential of its technologies to drive significant change in the scientific and environmental sectors. “Colossal is at the cutting edge of biotechnology, utilizing state-of-the-art genetic tools to bring back species that could have a major impact on our planet’s biodiversity and climate resilience,” said a spokesperson from TWG Global. “We are excited to support the company’s groundbreaking work as it continues to scale its efforts and lead the way in de-extinction.”
The Series C funding round attracted several other investors who share Colossal’s vision of using technology to restore ecosystems and address urgent environmental challenges. The new capital will be used to accelerate the development of Colossal’s de-extinction initiatives, enhance its gene-editing technologies, and expand its research efforts into additional species restoration projects. The funding will also support the company’s expansion into new global markets as it builds partnerships with conservation organizations, governments, and research institutions.
“We are thrilled to have the support of TWG Global and our other investors as we work to push the boundaries of what’s possible in genetic science,” said Ben Lamm, CEO of Colossal. “This funding will allow us to continue our work in resurrecting extinct species, while also advancing our broader goal of using genetic engineering to restore ecosystems and preserve biodiversity for future generations.”
In addition to its de-extinction efforts, Colossal is exploring ways to apply its technologies to other areas of genetic restoration, including disease prevention, conservation, and agriculture. By focusing on the intersection of genetic science and environmental sustainability, Colossal is positioning itself as a leader in the emerging field of ecological restoration through biotechnology.
The company’s ambitious work has captured the imagination of both the scientific community and the public, with its efforts to bring back long-lost species sparking both excitement and debate. As Colossal continues to lead the charge in genetic restoration, it is set to become a key player in addressing some of the most pressing challenges facing the planet, from species extinction to climate change.
With this new $200 million infusion, Colossal is well-equipped to further its groundbreaking work, pushing the frontiers of genetic engineering and paving the way for a future where extinct species could be restored to their natural habitats, helping to create a more biodiverse and resilient world.
